Wang Xuemei, Xie Ping, Sun Guojuan, Deng Zhumei, Zhao Min, Bao Shuting, Zhou Yunxia
Department of Gynecology, Hospital of Chengdu University of Traditional Chinese Medicine, College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine.
Department of Gynecology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, P. R. China.
Medicine (Baltimore). 2020 Aug 7;99(32):e21616. doi: 10.1097/MD.0000000000021616.
COVID-19 is a global public health emergency. At present, there is no highly effective medicine for the prevention and treatment of 2019-nCoV. Western medicine for COVID-19 is mainly based on symptomatic support therapy. Chinese herbal medicine has been used to prevent infectious diseases for thousands of years in China. Western medicine routine treatment combined with Chinese herbal medicine is an alternative clinical option but lacks evidence-based medical evidence. The systematic review protocol aims to formulate a research plan that can evaluate the efficacy and safety of western medicine routine treatment combined with Chinese herbal medicine for COVID-19.
We will search the following eight databases: Cochrane Library, PubMed, Embase, Medline, CNKI, Wanfang, VIP, and CBM. The search time is up to the end of July 2020. Two authors will independently complete literature screening, data extraction, and risk of bias assessment. In case of disagreement, the third author will assist in the judgment. The primary outcome will be the clinical cure rate. The secondary outcome will be accounting symptoms, fever time, time of virus nucleic acid turning negative, check the condition by drawing blood, pneumonia absorption rate, patient hospitalization time, severe conversion rate and case fatality rate, adverse reactions, and adverse events. Revman 5.3 will be used for systematic reviews and meta-analysis. The report of the protocol will follow the PRISMA-P statement, and the report of the systematic review and meta-analysis will follow the PRISMA statement.
We will provide evidence-based medical evidence of the efficacy and safety of western medicine routine treatment combined with Chinese herbal medicine for COVID-19. The findings will be published in peer-reviewed journals.
CRD42020190106.
新型冠状病毒肺炎（COVID-19）是全球突发公共卫生事件。目前，尚无预防和治疗2019新型冠状病毒（2019-nCoV）的高效药物。COVID-19的西医治疗主要基于对症支持治疗。中药在中国用于预防传染病已有数千年历史。西医常规治疗联合中药是一种可供选择的临床方案，但缺乏循证医学证据。本系统评价方案旨在制定一项研究计划，以评估西医常规治疗联合中药治疗COVID-19的疗效和安全性。
我们将检索以下八个数据库：考克兰图书馆、PubMed、Embase、Medline、中国知网（CNKI）、万方、维普和中国生物医学文献数据库（CBM）。检索时间截至2020年7月底。两名作者将独立完成文献筛选、数据提取和偏倚风险评估。如有分歧，第三位作者将协助判断。主要结局指标为临床治愈率。次要结局指标为症状计数、发热时间、病毒核酸转阴时间、抽血检查情况、肺炎吸收率、患者住院时间、重症转化率和病死率、不良反应及不良事件。将使用Revman 5.3进行系统评价和Meta分析。方案报告将遵循PRISMA-P声明，系统评价和Meta分析报告将遵循PRISMA声明。
我们将提供西医常规治疗联合中药治疗COVID-19疗效和安全性的循证医学证据。研究结果将发表在同行评审期刊上。
CRD42020190106。
